RxDoctor Payments Data

Gina Taylor

Family · Louisburg, NCNPI 1033855473

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 45 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$254
  • Johnson & Johnson$176
  • AstraZeneca$141
  • Lilly USA, LLC$135
  • GSK$72
  • Merck$67
  • plus $292 from 9 others

What the payments were for

  • Food & beverage$1,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,796
Medicare patients
42
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$38,749
OzempicSemaglutide25$35,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$29,123
FarxigaDapagliflozin Propanediol38$24,152
LinzessLinaclotide24$13,554
EliquisApixaban21$12,286
Repatha SureclickEvolocumab18$11,757
BelsomraSuvorexant12$5,114
VascepaIcosapent Ethyl14$2,126
Atorvastatin Calcium262$1,893
Gabapentin132$1,400
Albuterol Sulfate HfaAlbuterol Sulfate57$1,183
Amlodipine Besylate185$1,043
Losartan Potassium138$1,021
Divalproex Sodium ErDivalproex Sodium22$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$135$38,74932 claims
Novo NordiskOzempic$254$35,33125 claims
GSKTrelegy Ellipta$72$29,12344 claims
AstraZenecaFarxiga$141$24,15238 claims
PfizerEliquis$17$12,28621 claims
MerckBelsomra$67$5,11412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Louisburg

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →